

Julien J Torgue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5218821/publications.pdf>

Version: 2024-02-01

16
papers

748
citations

687220

13
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

591
citing authors

#	ARTICLE	IF	CITATIONS
1	²¹² Pb-conjugated anti-rat HER2/ <i>neu</i> antibody against a <i>neu</i> -N derived murine mammary carcinoma cell line: cell kill and RBE in vitro. International Journal of Radiation Biology, 2022, 98, 1452-1461.	1.0	4
2	Targeted β^- -Emitter Therapy with ²¹² Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. Journal of Nuclear Medicine, 2022, 63, 1326-1333.	2.8	58
3	Mathematical Modeling of In Vivo Alpha Particle Generators and Chelator Stability. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	0.7	5
4	Preclinical study of ²¹² Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. British Journal of Cancer, 2021, 125, 1657-1665.	2.9	11
5	Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate ²¹² Pb-NNV003. PLoS ONE, 2020, 15, e0230526.	1.1	22
6	Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clinical Cancer Research, 2019, 25, 4775-4790.	3.2	26
7	Preclinical Investigation of ²¹² Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model. Molecular Cancer Therapeutics, 2019, 18, 1012-1021.	1.9	46
8	Safety and Outcome Measures of First-in-Human Intraperitoneal β^- Radioimmunotherapy With ²¹² Pb-TCMC-Trastuzumab. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 716-721.	0.6	70
9	Toxicological Studies of ²¹² Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial. Pharmaceuticals, 2015, 8, 416-434.	1.7	16
10	Dose Escalation and Dosimetry of First-in-Human β^- Radioimmunotherapy with ²¹² Pb-TCMC-Trastuzumab. Journal of Nuclear Medicine, 2014, 55, 1636-1642.	2.8	102
11	Pharmacokinetics and Imaging of ²¹² Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 12-17.	0.7	106
12	Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using ²¹² Pb. PLoS ONE, 2013, 8, e69613.	1.1	54
13	Significant systemic therapeutic effects of high-LET immunoradiation by ²¹² Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. International Journal of Oncology, 2012, 40, 1881-8.	1.4	25
14	Bacterial origin recognition complexes direct assembly of higher-order DnaA oligomeric structures. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18479-18484.	3.3	57
15	Mutational analysis reveals <i>Escherichia coli</i> oriC interacts with both DnaA-ATP and DnaA-ADP during pre-RC assembly. Molecular Microbiology, 2007, 66, 428-439.	1.2	38
16	SeqA Blocking of DnaA-oriC Interactions Ensures Staged Assembly of the E. coli Pre-RC. Molecular Cell, 2006, 24, 581-592.	4.5	108